BioWorld

Oct. 28, 2003

View Archived Issues

Onyx, Bayer Start 9006 Phase III Program In Renal Cell Carcinoma

Onyx Pharmaceuticals Inc. and partner Bayer Corp. initiated a pivotal Phase III study in renal cell carcinoma with BAY 43-9006, a cancer candidate considered by some to be one of the most exciting products in development. (BioWorld Today) Read More

Dynavax Enters IPO Ring; Aims To Go Public With $90M Offering

Read More

Mycobacterium Tuberculosis Plays Tag With Key Genes, Proteins, Now New LRG-47 Likely Drug Candidate

Read More

Remicade's Phase III Data Support Label Expansion In Spinal Arthritis

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More